Jan 3 2023

Halberd Corporation 2022 Year End CEO Letter and 2023 Goals

By |2023-01-02T20:07:25-05:00January 3rd, 2023|Featured, Investor News, Press Releases, Update Letter|0 Comments

Profound Advancements Explained Jackson Center, PA, January 3, 2023 -- Halberd Corporation (OTC: HALB) The second half of 2022 was a very busy time. 2022 2nd HALF ACHIEVEMENTS Halberd’s previous research on development of a monoclonal antibody (mAb) against COVID-19 (SARS-COV-2) was found to enhance the effectiveness of the leading commercial COVID antibody by 44.4%. ...

Apr 25 2022

Halberd CEO Letter

By |2022-04-24T18:20:33-04:00April 25th, 2022|Featured, Investor News, News, Press Releases, Update Letter|0 Comments

Q1 Accomplishments and Q2 Plans Jackson Center, PA, April 25, 2022 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC: HALB) This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team. Q1 OVERVIEW AND ACHIEVEMENTS Halberd demonstrated elimination of the final two of the “Top Ten” antigens linked ...

Jan 25 2022

Halberd CEO Letter: 2021 Year-End & 2022 Outlook

By |2022-01-24T18:26:05-05:00January 25th, 2022|Investor News, Press Releases, Update Letter|0 Comments

Jackson Center, PA, January 25, 2022 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC: HALB) First of all I want to wish all of our shareholders and constituents a Very Healthy, Happy and Prosperous New Year! 2021 OVERVIEW AND ACHIEVEMENTS Halberd continued its R&D strategy to focus on biomedical areas where: There is ...

Jul 6 2021

Halberd Corporation CEO Letter

By |2021-07-05T22:28:30-04:00July 6th, 2021|Featured, Update Letter|0 Comments

Q2-21 Accomplishments and Q3 Plans Jackson Center, PA, July 6, 2021 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC-PINK: HALB) As we began the second quarter, the company, along with the rest of the country, was focused on developing antibodies against Covid-19 that could be used as therapeutic and/or diagnostic tools.  Because of ...

Go to Top